Oxygen sensing and conducted vasomotor responses in mouse cremaster arterioles in situ.
This study examines mechanisms by which changes in tissue oxygen tension elicit vasomotor responses and whether localized changes in oxygen tension initiates conducted vasomotor responses in mouse cremaster arterioles. Intravital microscopy was used to visualize the mouse cremaster microcirculation. The cremaster was superfused with Krebs' solution with different oxygen tensions, and a gas exchange chamber was used to induce localized changes in oxygen tension. In arterioles where red blood cells were removed by buffer perfusion, arterioles responded with same magnitudes of vasodilatation (DeltaD = 16.0 +/- 4.9 microm) when changing from high (PO(2) = 242.5 +/- 13.3 mm Hg) to low (PO(2) = 22.5 +/- 4.8 mm Hg) oxygen tension as seen in the intact cremaster circulation (DeltaD = 18.7 +/- 1.0 microm). Blockade of NO synthases by L: -NAME and adenosine receptors by DPCPX had no effects on vasomotor responses to low or high oxygen. Induction of localized low (PO(2) = 23.3 +/- 5.7 mmHg) or high (PO(2) = 300.0 +/- 25.7 mm Hg) oxygen tension caused vasodilatation or -constriction locally and at a site 1,000 microm upstream (distantly). Glibenclamide blocker of ATP-sensitive K(+) channels inhibited vasodilatation and -constriction to low (PO(2) = 16.0 +/- 6.4 mm Hg) and high (PO(2) = 337.4 +/- 12.8 mm Hg) oxygen tension. 1) ATP-sensitive K(+) channels seem to mediate, at least in part, vasodilatation and vasoconstriction to low and high oxygen tension; 2) Red blood cells are not necessary for inducing vasodilatation and vasoconstriction to low or high oxygen tension; 3) localized changes in the oxygen tension cause vasomotor responses, which are conducted upstream along arterioles in mouse cremaster microcirculation.
Ngo
Anh Thuc
AT
Division of Renal & Vascular Research, Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3, DK-2200, Copenhagen, Denmark. anhngo@sund.ku.dk
Jensen
Lars Jørn
LJ
Riemann
Mads
M
Holstein-Rathlou
Niels-Henrik
NH
Torp-Pedersen
Christian
C
D000241:Adenosine / Q000378:metabolism; D058916:Adenosine A1 Receptor Antagonists; D058917:Adenosine A2 Receptor Antagonists; D000818:Animals; D001160:Arterioles / Q000293:injuries / Q000378:metabolism; D015687:Cell Hypoxia; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004912:Erythrocytes / Q000378:metabolism; D054086:KATP Channels / Q000037:antagonists & inhibitors / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008833:Microcirculation; D018715:Microscopy, Video; D009132:Muscles / Q000098:blood supply*; D009569:Nitric Oxide / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000378:metabolism; D010100:Oxygen / Q000097:blood / Q000378:metabolism*; D010477:Perfusion; D026902:Potassium Channel Blockers / Q000494:pharmacology; D043682:Receptor, Adenosine A1 / Q000378:metabolism; D043683:Receptors, Adenosine A2 / Q000378:metabolism; D012039:Regional Blood Flow; D014661:Vasoconstriction / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects
D058916:Adenosine A1 Receptor Antagonists; D058917:Adenosine A2 Receptor Antagonists; D004791:Enzyme Inhibitors; D054086:KATP Channels; D026902:Potassium Channel Blockers; D043682:Receptor, Adenosine A1; D043683:Receptors, Adenosine A2; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D000241:Adenosine; D010100:Oxygen
J Physiol. 1995 Feb 15;483 ( Pt 1):29-39
7539841
Naunyn Schmiedebergs Arch Pharmacol. 1987 Aug;336(2):204-10
2825043
J Invest Dermatol. 1989 Oct;93(4):528-31
2506289
J Appl Physiol (1985). 2005 Nov;99(5):1866-71
16037400
Prog Biophys Mol Biol. 2003 Feb;81(2):133-76
12565699
Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12441-5
8618917
Cardiovasc Res. 1999 Jan;41(1):229-36
10325970
Microcirculation. 2002 Dec;9(6):443-62
12483542
Med Sci Sports Exerc. 2004 Jan;36(1):35-41
14707765
Am J Physiol Heart Circ Physiol. 2000 Apr;278(4):H1294-8
10749727
Nat Med. 2003 Dec;9(12):1498-505
14595407
Math Biosci. 1981 Aug;55(3-4):231-246
28943659
Hypertension. 1993 Apr;21(4):491-7
8384604
Br J Pharmacol. 1997 Feb;120(4):728-34
9051315
J Physiol. 1999 Jan 1;514 ( Pt 1):151-62
9831723
Acta Physiol Scand. 1987 Dec;131(4):507-15
3442240
Microvasc Res. 1999 Sep;58(2):99-107
10458925
Am J Physiol. 1994 Jun;266(6 Pt 2):H2508-14
8024012
Acta Physiol Scand. 2000 Apr;168(4):505-10
10759587
Circ Res. 2002 Nov 29;91(11):1046-55
12456491
Am J Physiol. 1991 Mar;260(3 Pt 2):H862-8
2000980
Am J Physiol Heart Circ Physiol. 2002 Jan;282(1):H380-8
11748085
Br J Pharmacol. 2005 Aug;145(8):1069-75
15912128
Am J Physiol. 1998 Jan;274(1):H382-3
9458890
Am J Physiol Heart Circ Physiol. 2008 Oct;295(4):H1562-71
18689501
J Physiol. 2002 Oct 1;544(Pt 1):195-209
12356892
Acta Physiol Scand. 1999 Sep;167(1):11-21
10519972
J Physiol. 2001 Nov 1;536(Pt 3):937-46
11691885
Am J Physiol. 1982 Apr;242(4):H688-97
7065281
J Appl Physiol (1985). 2005 Apr;98(4):1177-84
15772057
Am J Respir Crit Care Med. 1998 Aug;158(2):477-83
9700124
J Physiol. 1999 Jan 1;514 ( Pt 1):163-75
9831724
Biochem J. 2001 Aug 1;357(Pt 3):593-615
11463332
Hypertension. 1994 Jun;23(6 Pt 2):1113-20
8206602
Curr Pharm Des. 2005;11(15):1915-40
15974968
J Physiol. 1996 Apr 15;492 ( Pt 2):495-503
9019545
J Vasc Res. 2003 Jan-Feb;40(1):68-76
12644727
Circ Res. 2003 Apr 18;92(7):793-800
12637364
Br J Pharmacol. 2006 Feb;147(4):455-8
16341231
Science. 1990 Mar 16;247(4948):1341-4
2107575
Circ Res. 1983 Oct;53(4):515-25
6627610
Am J Physiol Heart Circ Physiol. 2001 Jun;280(6):H2833-9
11356642
Microvasc Res. 1983 Jan;25(1):108-31
6835096
J Appl Physiol (1985). 2004 Sep;97(3):1152-8
15169746
Microcirculation. 2000 Apr;7(2):137-45
10802856
Circ Res. 1970 Nov;27(5):669-78
5486243
FASEB J. 2000 Jan;14(1):197-207
10627294
Microcirculation. 2005 Jan-Feb;12(1):33-45
15804972